Agenus Inc news

   Watch this stock
Showing stories 1 - 10 of about 83   

Articles published

AGEN 2.99 +0.02 (0.58%)
price chart
Why Agenus Inc. Shares Tumbled
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
GSK's MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Non-Small Cell ...  Business Wire (press release)
Glaxo Cancer Vaccine Fails, Testing Continues  Fox Business
Related articles »  
Why Agenus Inc. Stock Skyrocketed
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Agenus Rallies On Brain Cancer Vaccine Results  Bidness Etc
Agenus Brain Cancer Vaccine Shows Extended Survival in Phase 2 Final Data ...  Business Wire (press release)
Related articles »  
Why Agenus Inc. Stock Briefly Spiked Higher
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
UPDATE: Agenus Vaccine Shows Significant Reduction in Viral Burden after ...  Benzinga
Maxim Keeps Agenus (AGEN) at Buy, Comments on HerpV Phase 2 Results  StreetInsider.com (subscription)
Related articles »  
Agenus Inc.: Ingeniously Designed Vaccines To Galvanized Tomorrow's Medicine
Agenus Inc. (AGEN), headquartered in Lexington, Massachusetts, is an immune-oncology biopharmaceutical company focused on the development of innovative technologies and products aimed at treating cancers and infectious disease by helping the ...
Agenus Reports Second Quarter 2014 Financial Results  MarketWatch
Related articles »  
Agenus Inc - A Potential New Play On Ebola
Shares of Agenus Inc (NASDAQ: AGEN) have moved to the upside in Monday's trade as the company is being mentioned as a potential play on Ebola.
Related articles »  
Agenus Inc. (AGEN) Soars: Stock Adds 10.3% in Session
Agenus Inc. (AGEN - Snapshot Report) was a big mover last session, as the company saw its shares rise by over 10% on the day.
Related articles »  
UTHSC Tests Agenus Inc.'s New Immune Boosting Melanoma Therapies
Agenus Inc. has announced the initiation of the Phase 2 clinical trial at the University of Texas Health Science Center at Houston to test its immune boosting melanoma drugs.
Related articles »  
Agenus Inc. (AGEN) Jumps 8.46% on October 15
Agenus Inc. (AGEN) was among the biggest gainers on the Russell 2000 for October 15 as the stock popped 8.46% to $2.95, representing a gain of $0.23 per share.
Agenus Inc. (AGEN) Buy Rating Reiterated at H.C. Wainwright
H.C. Wainwright reiterated a Buy rating on Agenus Inc. (NASDAQ: AGEN) with a price target of $6.00. Comments follow phase 2 Prophage data.
Agenus Inc. (AGEN) Catches Eye: Stock Surges 10.5%
Agenus Inc. (AGEN - Snapshot Report) was a big mover last session, as the company saw its shares surge nearly 11% on the day.